| Aug 30 |
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
|
| Aug 15 |
Aptose Announces Adjournment of its Special Meeting of Shareholders
|
| Aug 8 |
Aptose Biosciences GAAP EPS of -$0.43 beats by $0.15
|
| Aug 8 |
Aptose Biosciences: Q2 Earnings Snapshot
|
| Aug 8 |
Aptose Reports Results for the Second Quarter 2024
|
| Jul 19 |
Aptose receives deficiency notice from Nasdaq
|
| Jul 19 |
Aptose Announces Receipt of Deficiency Notice from Nasdaq
|
| Jun 18 |
Aptose Announces Results from Annual and Special Meeting of Shareholders
|
| Jun 14 |
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
|
| Jun 13 |
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
|
